Conference Report

Clinical Update on the Treatment of Colorectal Cancer

Source: CCO Independent Conference Coverage of the 2007 Gastrointestinal Cancers Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Update on the Treatment of Colorectal Cancer

Faculty:
Richard M. Goldberg, MD John L. Marshall, MD

CME CREDIT INFORMATION

Release Date: 03/20/07

Expiration Date: 03/19/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify trends in the management of metastatic colorectal cancer, including the use of novel combinations, therapies, and modified dosing strategies with targeted agents
Discuss the results of studies investigating the use of gene analysis for therapy selection in patients with colorectal cancer
Describe studies investigating quality-of-care standards for patients with colorectal cancer

Topics covered include:

Cetuximab Dose Escalation
XELOX-1/NO16966
STAR-01: Preliminary Toxicity Data
Benefit of Preoperative PET
Metastasectomy Following Bevacizumab Treatment
ACCENT: Prognostic Factors for Survival
Oxaliplatin-Associated Liver Toxicity
Patient-Provider Communication
UGT1A1*28 Genotype and Irinotecan Dose
Inadequate Documentation of Colorectal Cancer Quality Measures

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.